Spago Nanomedical’s strategy is to utilize our expert capabilities in chemistry and nanomedicine to develop our projects into human clinical trials. The business model is based on outlicensing or strategic partnering with industrial actors who maintain capabilities to proceed development up to registration and commercialization. This reduces the internal need of capital as well as maximizing the potential for successful market penetration.
Our vision is to engage in competitive and successful development of products for increased survival and quality of life for cancer patients and thereby create long-term profitability for the company and its owners.
Our goal is to become a profitable and leading company within cancer diagnostics and therapy based on nanomedicine through the development of products that provide good health economics and meet unmet medical needs.